Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 56
Healthy volunteers: yes

Brief summary:
To establish the bioequivalence and adhesion properties of transdermal clonidine prepared with Oppanol® brands of polyisobutylene (PIB) vs. transdermal clonidine prepared with VistanexTM brands of polyisobutylene (PIB) in healthy male and female volunteers.

Detailed description:

Arms:
arm 1: subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1) arm 2: subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1) arm 3: subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously

Interventions: intervention 1: Catapres-TTS-1 intervention 2: Intervention 1: Catapres-TTS-3 intervention 3: Intervention 1: Catapres-TTS-3 intervention 4: Intervention 2: Catapres-TTS-3 intervention 5: Catapres-TTS-1 intervention 6: Intervention 2: Catapres-TTS-3
Intervention descriptions: intervention 1: Catapres-TTS-1 Oppanol intervention 2: Catapres-TTS-3 Oppanol intervention 3: Catapres-TTS-3 Oppanol intervention 4: Catapres-TTS-3 Vistanex intervention 5: Catapres-TTS-1 Vistanex intervention 6: Catapres-TTS-3 Vistanex

Protocol document: